These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22151964)

  • 1. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study.
    Ng Wing Tin S; Martin-Duverneuil N; Idbaih A; Garel C; Ribeiro M; Parker JL; Defachelles AS; Lambilliotte A; Barkaoui M; Munzer M; Gardembas M; Sibilia J; Lutz P; Fior R; Polak M; Robert A; Aumaitre O; Plantaz D; Armari-Alla C; Genereau T; Berard PM; Talom GN; Pennaforte JL; Le Pointe HD; Barthez MA; Couillault G; Haroche J; Mokhtari K; Donadieu J; Hoang-Xuan K;
    Orphanet J Rare Dis; 2011 Dec; 6():83. PubMed ID: 22151964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.
    Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ
    Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.
    Allen CE; Flores R; Rauch R; Dauser R; Murray JC; Puccetti D; Hsu DA; Sondel P; Hetherington M; Goldman S; McClain KL
    Pediatr Blood Cancer; 2010 Mar; 54(3):416-23. PubMed ID: 19908293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Langerhans' cell histiocytosis in adults: a clinical and therapeutic analysis of 11 patients from a single institution.
    Giona F; Caruso R; Testi AM; Moleti ML; Malagnino F; Martelli M; Ruco L; Giannetti GP; Annibali S; Mandelli F
    Cancer; 1997 Nov; 80(9):1786-91. PubMed ID: 9351548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
    Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
    Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck manifestation and prognosis of Langerhans' cell histiocytosis in children.
    Nicollas R; Rome A; Belaïch H; Roman S; Volk M; Gentet JC; Michel G; Triglia JM
    Int J Pediatr Otorhinolaryngol; 2010 Jun; 74(6):669-73. PubMed ID: 20363036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteatoma secondary to temporal bone involvement by Langerhans cell histiocytosis: a complication amenable to curative surgery.
    Roger G; Dupré M; Leboulanger N; Godey B; Thomas C; Gandemer V; Bordure P; Garabedian EN; Donadieu J
    Otol Neurotol; 2009 Feb; 30(2):190-3. PubMed ID: 19169133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Langerhans cell histiocytosis in children less than 2 years of age.
    Kusuma Kumary P; Priyakumari T; Chellam VG; James FV; Nair MK
    Indian Pediatr; 1999 Jan; 36(1):29-36. PubMed ID: 10709120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions.
    Cantu MA; Lupo PJ; Bilgi M; Hicks MJ; Allen CE; McClain KL
    PLoS One; 2012; 7(8):e43257. PubMed ID: 22916233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis.
    Gavhed D; Laurencikas E; Akefeldt SO; Henter JI
    Acta Paediatr; 2011 Jul; 100(7):e36-9. PubMed ID: 21166862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
    Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience.
    Kobayashi M; Ando S; Kawamata T; Makiyama J; Yokoyama K; Imai Y; Tojo A
    Int J Hematol; 2020 Aug; 112(2):185-192. PubMed ID: 32514929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
    Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
    Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.